GSK stock fell early Wednesday on light sales of two key vaccines, Shingrix and Arexvy, though the company otherwise beat expectations.

The post GSK Beats Second-Quarter Views, Raises Outlook; But Shares Fall On Shingrix Miss appeared first on Investor’s Business Daily.